Effective on trade date Thursday, January 2, 2020, and pending all relevant CFTC regulatory review periods, this Market Regulation Advisory Notice will supersede CME Group Market Regulation Advisory Notice RA1812-5 from November 5, 2018. It is being issued based on an amendment to Rule 512.C. (“Hearings and Appeals”) that replaces a reference to the Probable Cause Committee, which is being eliminated, with a reference to the Chief Regulation Officer.[1]
Click HERE to view the full advisory.